Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_assertion type Assertion NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_head.
- NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_assertion description "[Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_provenance.
- NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_assertion evidence source_evidence_literature NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_provenance.
- NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_assertion SIO_000772 22343387 NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_provenance.
- NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_assertion wasDerivedFrom befree-20140225 NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_provenance.
- NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_assertion wasGeneratedBy ECO_0000203 NP435524.RA5K2jOPlOejQ3s_TVjbo8QZrbHISS7Fh4cXRE3vxKRfg130_provenance.